San Jose, CA (Vocus/PRWEB) April 13, 2011
GIA announces the release of a comprehensive global report on RNA Interference markets. The global market for RNA Interference (RNAi) is forecast to reach $4.04 billion by the year 2017. The market for RNAi is driven by the increasing use of this technology as a research tool in functional genomics, that finds applications in drug discovery, target validation, and drug development, in addition to agricultural and plant biotechnology sectors. The market for RNA interference in the long-term is expected to be primarily driven by the development of RNAi-based therapeutics for various diseases.
RNA Interference (RNAi), a breakthrough biological phenomenon unraveled in the late 1990s, represents a promising technology with immense possibilities in the area of drug development for multiple indications. The effects of RNA interference have demonstrated the role of this process in regulation and silencing of specific endogenous gene activity as well as exogenous parasitic genes, and their genetic components inside a cell. The components (namely siRNA and miRNA) involved in this path breaking process are expected to become a new wide-ranging class of drugs, on the lines of monoclonal antibodies and small molecules, for the treatment of serious diseases such as cancer, viral infections, and genetic and neurological disorders. In addition to identifying druggable targets, RNAi could also be exploited in a number of applications, including research in functional genomics, disease diagnostics, and agriculture, among others. Over the years, the use of siRNA and miRNA in industries and academic institutions has witnessed a substantial growth.
The US and Europe together account for a lion’s share of the global RNAi market, as stated by the new market research report on RNA Interference (RNAi). The US represents the single largest market. Europe constitutes the second largest as well as fastest growing market, growing at a compounded annual rate of 13.6% over the analysis period. Application-wise, RNAi in drug discovery and target validation, and RNAi reagents together dominate the RNAi market. However, in the coming years, RNAi reagent is expected to constitute the largest area of RNAi application. siRNA synthesis is expected to emerge as the fastest growing application area, with a CAGR of more than 15% over the analysis period.
Presently in the nascent stages, the RNAi industry is gaining ground in the therapeutics arena, with its most promising application being high-throughput screening. Given the role played by RNA interference in selective regulation and gene silencing, and the fact that it is a naturally occurring phenomenon in a number of organisms, RNAi-based therapeutics could potentially target a broad range of proteins, compared to a small class of proteins targeted by existing classes of drugs. Druggable targets for RNAi-based therapeutics could be easily identified using bioinformatics tools, in comparison to extensive lead optimization techniques required in the case of existing classes of drugs such as protein therapeutics and small molecules. The ease of identifying drug targets using bioinformatics is expected to drive the growth of RNAi-based therapeutics development. The first of the approved RNAi-based drugs are expected to foray into the therapeutics market in 2013. RNAi-based therapeutics, however, pose several challenges, the most prominent and still persistent being drug delivery. In addition, safety and efficacy, stability, and stimulation of non-specific immune response are also issues of concern with RNAi therapeutics. With an expected change in the patents and licenses scenario in the pharmaceutical industry, it is likely that more companies would explore RNAi technology to provide RNAi based products.
Major players profiled in the report include Alnylam Pharmaceuticals Inc., Benitec Limited, Bioneer Corp., Calando Pharmaceuticals Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon Inc., Dicerna Pharmaceuticals Inc., Genesis Research & Development Corporation Limited, OPKO Health Inc., Polyplus-transfection SA, Quark Pharmaceuticals Inc., among others.
The research report titled “RNA Interference (RNAi): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the RNA Interference, its applications, industry overview, industry outlook, regulatory approvals, technological innovations, recent industry activity, and profiles of major/niche global market participants. The report provides annual value sales estimates and projections for RNA Interference market for the years 2009 through 2017 for the following application areas - Drug Discovery and Target Validation, Reagents, and siRNA synthesis. Also, a seven-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/RNA_interference_RNAi_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/